Next Article in Journal
SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia
Next Article in Special Issue
Evaluation of HPV-Related Biomarkers in Anal Cytological Samples from HIV-Uninfected and HIV-Infected MSM
Previous Article in Journal
Nucleosome Positioning on Episomal Human Papillomavirus DNA in Cultured Cells
Previous Article in Special Issue
Metabolic Reprogramming in Cancer: Role of HPV 16 Variants
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 10
Issue 6
10.3390/pathogens10060773
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

E6/E7 Variants of Human Papillomavirus 16 Associated with Cervical Carcinoma in Women in Southern Mexico

by
Ramón Antaño-Arias
1,
Oscar Del Moral-Hernández
2,
Julio Ortiz-Ortiz
1,
Luz Del Carmen Alarcón-Romero
3,
Jorge Adán Navor-Hernández
1,
Marco Antonio Leyva-Vázquez
1,
Marco Antonio Jiménez-López
4,
Jorge Organista-Nava
1 and
Berenice Illades-Aguiar
1,*
1
Laboratorio de Biomedicina Molecular de la Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero CP 39090, Mexico
2
Laboratorio de Virología de la Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero CP 39090, Mexico
3
Laboratorio de Citopatología e Histoquímica de la Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero CP 39090, Mexico
4
Instituto Estatal de Cancerología “Dr. Arturo Beltrán Ortega” Acapulco, Guerrero CP 39570, Mexico
*
Author to whom correspondence should be addressed.
Pathogens 2021, 10(6), 773; https://doi.org/10.3390/pathogens10060773
Submission received: 26 May 2021 / Revised: 18 June 2021 / Accepted: 18 June 2021 / Published: 20 June 2021
(This article belongs to the Special Issue HPV Molecular Diagnostics: Laboratory, Research, and Clinical Aspects)
Review Reports Versions Notes

Abstract

:
Persistent infection with the human papillomavirus 16 (HPV 16) is the cause of half of all cervical carcinomas (CC) cases. Moreover, mutations in the oncoproteins E6 and E7 are associated with CC development. In this study, E6/E7 variants circulating in southern Mexico and their association with CC and its precursor lesions were evaluated. In total, 190 DNA samples were obtained from scrapes and cervical biopsies of women with HPV 16 out of which 61 are from patients with CC, 6 from patients with high-grade squamous intraepithelial lesions (HSIL), 68 from patients with low-grade squamous intraepithelial lesions (LSIL), and 55 from patients without intraepithelial lesions. For all E7 variants found, the E7-C732/C789/G795 variant (with three silent mutations) was associated with the highest risk of CC (odd ratio (OR) = 3.79, 95% confidence interval (CI) = 1.46–9.85). The analysis of E6/E7 bicistron conferred to AA-a*E7-C732/C789/G795 variants revealed the greatest increased risk of CC (OR = 110, 95% CI = 6.04–2001.3), followed by AA-c*E7-C732/C789/G795 and A176/G350*E7-p. These results highlight the importance of analyzing the combinations of E6/E7 variants in HPV 16 infection and suggest that AA-a*E7-C732/C789/G795, AA-c*E7-C732/C789/G795, and A176/G350*E7-p can be useful markers for predicting CC development.

1. Introduction

Persistent infection with high-risk human papillomavirus (HR-HPV) is the main cause of cervical carcinoma (CC) and its precursor lesions [1]. Among the HR-HPV types, HPV 16 causes more than half of CC cases worldwide [2,3].
The oncogenicity of HPV 16 is because of the oncoproteins E6 and E7, which promotes cell transformation and immortalization; increase cell proliferation; invasion and migration; and supports immune evasion. E6 induces p53 degradation and prevents cell growth arrest and apoptosis. E7 binds to retinoblastoma proteins p107 and p130 and causes immortalization and deregulation of cell proliferation and differentiation. Hence, these oncoproteins act together to promote cervical carcinogenesis [4,5,6].
E6 and E7 genes are located in tandem at the beginning of the HPV 16 genome at nucleotides 104–559 and 562–858, respectively [7], and are initially transcribed as a single bicistronic HPV 16 E6/E7 pre-mRNA. Mature mRNA from the unspliced HPV 16 E6/E7 bicistron encodes both oncoproteins, spliced transcripts, and E6*I/E7 and E6*II/E7, which are short forms of E6 with intact E7 [8,9].
HPV 16 belongs to the genus Alphapapillomavirus, species group A9 [10]. It has intratypic variants associated with premalignant lesion progression and CC development [11,12,13,14]. HPV 16 variants have been classified into four lineages: A (European-Asian, EAS), B (African 1, AF1), C (African 2, AF2), and D (North-American/Asian-American, NA/AA). Furthermore, nine sublineages have been described: A1, A2, A3 (European, E), A4 (Asian, As), B1 (Afr1a), B2 (Afr1b), D1 (North-American, NA), D2 (Asian-American, AA1), and D3 (Asian-American, AA2) [12,15]. Most infections worldwide are caused by sublineages A1, A2, and A3 [15,16]. However, sublineage D2 is closely associated with the risk of CC [14].
In Mexico, several E6 variants of HPV 16 have been characterized. In Mexico City, the variants E-G131 (A1) E-G350, E-C188, E-A176 (A2), NA1 (D1), AA-a, and AA-c (D2) were reported and among them the AA variants are more oncogenic than the E variants [17]. In other studies, only the E-G350 (A2) variant was reported [18,19]. In southeastern Mexico, E-Prototype (A1), E-G350 (A2), Af2 (C), and AA (D2) were reported in samples from women with CC [20]. Moreover, in southern Mexico, we previously detected 27 E6 variants of HPV 16 and among them the most frequent and most closely associated with the development of CC were E-G350, E-C188/G350, E-176/G350 (A2), and AA-a and AA-c (D2) [21]. These HPV 16 E6 variants alter the expression of genes involved in proliferation, differentiation, apoptosis, cell cycle, adhesion, angiogenesis, transcription, and protein translation in C33-A cells and are consistent with the oncogenic potential of HPV 16 variants [22].
To date, few studies have focused on the intratypical variants of E7 as compared with those on E6 variants. Nevertheless, several studies demonstrated that non-synonymous mutations in E7 gene can cause amino acid changes. In particular, the variants A647G (NS29) and C749T (S63F) are associated with the progression of premalignant lesions into CC [23,24,25]. However, in a large study, E7 conservation was found to be significantly associated with CC, whereas E7 mutations were associated with reduced carcinogenicity of HPV 16 [13].
Taken together, a deeper understanding of the regional variants of HPV 16 is needed owing to their important epidemiological, preventive, and therapeutic implications for CC. Hence, the present study had aimed to perform the following: (1) to characterize the E7 genetic variations (since E6 variants circulating in southern Mexico have already been reported); (2) to determine the combinations of E6 and E7 variants in the HPV 16 E6/E7 bicistron in women from southern Mexico; and (3) evaluate the associations between the observed variants alone and in combination with the development of CC and precursor lesions.

2. Results

A total of 190 HPV 16 positive women (aged between 17 and 97 years) were included in the study. All participants were residents from the seven regions of the Guerrero state in southern Mexico. The average age of women with CC, high-grade squamous intraepithelial lesions (HSIL), low-grade squamous intraepithelial lesions (LSIL), and without intraepithelial lesions was 50.5, 36.3, 30.2, and 35.9 years, respectively. The clinical and demographic characteristics of the patients are presented in Table 1.

2.1. E7 Variants of HPV 16

E7 variants in HPV 16 identified in women in southern Mexico with CC, HSIL, LSIL, and non-intraepithelial lesions were analyzed. Eight E7 mutations were found and comprises two missense mutations (A647G and C712A) and six synonymous mutations (G666A, T678C, T732C, C765T, T789C, and T795G). The E7 prototype was detected most frequently (74.74%), followed by the E7-C732/C789/G795 variant (20.53%) with three silent mutations and a genotype that was associated with the highest risk of CC (odd ratio (OR) = 3.79, 95% confidence interval (CI) = 1.46–9.85). Other variants with synonymous mutations were detected, including E7-A666 (2.11%), E7-C678 (0.53%), and E7-T765 (0.53%). Variants with non-synonymous mutations were found in 2.11% (A712) and 0.53% (G647) of the samples (Table 2).

2.2. E6/E7 HPV 16 Bicistronic Variants of HPV 16

E6 and E7 variant combinations in the HPV E6/E7 bicistron were analyzed and grouped by sublineage. Four of the nine HPV 16 sublineages were present in the studied population: A1 (12.63%), A2 (66.84%), C1 (0.53%), and D2 (20%).
Mutations in the E6 and E7 genes of HPV 16 were identified in the same patient, and 34 bicistron combinations were detected. The most frequent combination of E6/E7 variants in HPV 16 was the E-G350*E7-prototype (36.8%), which belongs to the A2 sublineage, and the second most frequent combination was AA-a*E7-C732/C789/G795 (10%), which belongs to the D2 sublineage. Only 9.5% of the samples had a combination of E6 and E7 prototypes (Table 3).
In order to determine the effect of the combination of E6 and E7 variants in women infected with HPV 16, the risk of CC and its precursor lesions was analyzed. The risk of CC was highest in individuals harboring AA-a*E7-C732/C789/G795 (OR = 110, 95% CI = 6.04–2001.3), AA-c*E7-C732/C789/G795 (OR = 35, 95% CI = 2.63–465.37), and E-A176/G350*E7-prototype (OR = 23.33, 95% CI = 1.99–273.3). The oncogenic risk of the most common bicistronic variant, the E-G350*E7-prototype, was not statistically significant. The risk of developing CC precursor lesions was not significant for any of the E6/E7 combinations. The E-prototype*E7-prototype bicistron was used as a reference (Table 3).

3. Discussion

The aim of this study was to improve our understanding of HPV 16 variants circulating in southern Mexico owing to its epidemiological, preventive, and therapeutic implications for CC. We have previously reported that the most frequent E6 variants of HPV 16 and those associated with a high risk of developing CC were the European A1 and A2 sublineages (E-G350, E-prototype, E-A176/G350, and E-C188/G350) and Asian-American D2 (AA-a and AA-c) lineages [21]. This is the first study of E7 variants in HPV 16 in Mexico involving the analyses of variant combinations in the HPV E6/E7 bicistron in cervical samples as well as their association with the development of CC and its precursor lesions.
Herein, fewer variants were detected in E7 than in E6 of HPV 16, which in agreement with a previous report [21]. In addition to the numerical difference, only two variants identified—A712 (H51N) and G647 (N29S)—altered the E7 amino acid sequence and were detected at a very low frequency in southern Mexico. However, all the E6 variants showed amino acid changes [21].
Mutations in E7 herein identified were mostly synonymous (G666A, T678C, T732C, C765T, T789C, and T795G). Although these mutations do not change the amino acid residues of the oncoprotein, they are present at a high frequency in CC as is the case with the E7-C732/C789/G795 variant, which is associated with a 3.79 times higher risk of developing this pathology than compared with the E7-prototype. Moreover, E7-C732/C789/G795 was the second most frequent variant after the E7-prototype. What is noteworthy is that these three silent mutations were previously reported in Panama, United States, Suriname, Thailand, and India where they were found in patients with CC [26,27,28,29,30]. However, these reports did not evaluate the potential associations between the C732/C789/G795 variants in E7 of HPV 16 and the development of CC. The E7 variant that was previously reported to be associated with CC was E7-G647 [24,31], while in this study it was E7-C732/C789/G795. Although synonymous mutations do not modify the amino acid sequence of the oncoprotein, they may affect the structure, splicing, or stability of the RNA [32,33], thus contributing to oncogenicity; however, further studies are required to evaluate the precise effects. Taken together, these data emphasize the importance of analyzing local E7 variants and their association with the development of CC.
The distribution of HPV 16 E7 variants differs worldwide. In the American continent, the most reported variant is E7-C732/C789/G795; in Africa, it is E7-C789/G795; in Asia, they are E7-G647/C846, E7-G647, E7-C646, E7-A666, and E7-C732/C789/G795; and in Europe they are E7-C732/T749/G795, E7-G822, and E7-C789/G795 (Table 4). In this study, the most frequent E7 variant was E7-C732/C789/G795, which concurs with what has been reported in other countries in the American continent.
The complementary and synergistic effects of the HPV 16 oncoproteins E6 and E7 play a critical role in malignant transformation and cell immortalization [1]. There is extensive evidence that HPV 16 E6 and E7 mutations influence persistence, progression to precursor lesions, and the development of CC [12]. The differential oncogenic risk among variants of each oncoprotein has been studied; however, it is also necessary to analyze the oncogenic risk of combinations of E6/E7 variants.
One of the few studies on the oncogenic risk of the E6/E7 variant combination in HPV 16 focused on Korean women, in which the E6 T178G and E7 A647G (As*E7-G647) combination was the most prevalent and showed a significant association with the severity of cervical neoplasia [24]. In the present study, we found that individuals carrying the AA-a*E7-C732/C789/G795 combination possess the highest risk of CC (OR = 110), further suggesting that there may be a synergistic effect between the loci, as is evidenced by the lower risk for each locus individually (OR = 69.01 for AA-a of E6 [21] and 3.79 for E7-C732/C789/G795 in this study). The combinations of AA-c*E7-C732/C789/G795 and E-A176/G350*E7-prototype were also related to the risk of progression of precursor lesions to CC.
In conclusion, this is the first study of E7 variants of HPV 16 in Mexican women. Notably, E7-C732/C789/G795, a variant with three silent mutations, was associated with the risk of developing CC. These results highlight the importance of analyzing combinations of E6 and E7 variants in HPV 16 and suggest that AA-a*E7-C732/C789/G795, AA-c*E7-C732/C789/G795, and E-A176/G350*E7-prototype can be useful markers for predicting the progression of premalignant lesions and CC development.

4. Materials and Methods

4.1. Clinical Specimens and Diagnosis

The study enrolled 190 women, aged between 17 and 97 years old, who had all been identified as HPV 16 positive and were all residents of the Guerrero state in southern Mexico. Overall, 61 samples were from patients with CC, 6 samples were from patients with HSIL, 68 samples were from patients with LSIL, and 55 samples were from patients with no intraepithelial lesions. Cervical samples were obtained between 1997 and 2015 from cervical biopsies with histological diagnosis according to the FIGO classification system [65] or from cervical scrapes, with cytological diagnosis according to the Bethesda system [66]. Cervical scrapes (LSIL and no intraepithelial lesions) were collected using cytobrushes in a lysis buffer (10 mM Tris pH 8.0, 20 mM EDTA pH 8.0 and 0.5% sodium dodecyl sulfate) and the biopsies of women with HSIL or CC were immediately eluted in phosphate-buffered saline and stored at −70 ℃ until DNA extraction. DNA extraction was performed as previously described [67]. Briefly, the SDS-proteinase K-phenol-chloroform method [68] was used for DNA extraction from cervical scrapes and biopsies and the DNA was stored at −20 ℃ until analysis. The DNA integrity was evaluated by the amplification of the beta-globin gene [69]. All women without HPV 16 infection or from whom amplification of E6 and E7 genes was not obtained were excluded from the analysis. This study was approved by the Bioethical Committee of the Autonomous University of Guerrero and informed consent was obtained from all participants when the samples were collected.

4.2. Identification of HPV 16 E6/E7 Bicistronic Variants

E6 variants were identified as previously described [21]. HPV 16 E7 gene was amplified using the primers E7-F509 (5′-TGTATGTCTTGTTGCAGA-3′) and E7-R917 (5′-CATCCATTACATCCCGTA-3′), which amplify a 409 bp region. Polymerase chain reaction (PCR) was performed in a final volume of 25 µL containing the DNA template, 2.5 µL of 10× PCR buffer, 0.3 mM dNTPs, 1 mM MgCl2, 0.36 µM of each primer, and 0.7 U Maxima Hot Start Taq DNA Polymerase (EP0602; Thermo Fisher Scientific, Waltham, MA, USA). For positive and negative controls, reactions with 300 ng of DNA from SiHa or CaSki cells and H2O, respectively, were performed. PCR was performed using a Mastercycler EP Gradient (Eppendorf, Hamburg, Germany) as follows: initial denaturation at 95 ℃ for 4 min, followed by 40 cycles of 60 s at 95 ℃ for denaturation, 30 s at 57 ℃ for E6 and 51 ℃ for E7 for annealing, and 30 s at 72 ℃ for extension, with a final extension at 72 ℃ for 5 min. Correct amplification products were verified using DNA electrophoresis in an agarose gel.
Sequencing was performed using Big Dye Terminator V3.1 Cycle Sequencing (Applied Biosystems, Waltham, MA, USA) and the PCR products were purified using 75% isopropanol and loaded onto an ABI Prism 310 Genetic Analyzer (Applied Biosystems) according to the manufacturer’s instructions. All sequences were analyzed and aligned using Finch TV v. 1.4.0 (Geospiza Inc., Denver, CO, USA) and William Pearson’s LALIGN (https://embnet.vital-it.ch/software/LALIGN_form.html, accessed on 19 June 2021), respectively. The FASTA sequence of the reference HPV 16 NC 1526.3 was used for the alignment and for the identification of E7 variants. Sequence data are publicly available in the GenBank database (accession numbers: MW452666-MW452855).

4.3. Statistical Analysis

Data was analyzed using the STATA v.11 software (StataCorp, College Station, TX, USA). Chi-square test was performed for analyzing E7 and E6/E7 genetic variants and lesions. The age-adjusted ORs and 95% CI were calculated for the E7 variant and E6/E7 bicistronic variants. Statistical significance was set at p < 0.05.

Author Contributions

Conceptualization, B.I.-A. and R.A.-A.; methodology, R.A.-A., O.D.M.-H., and M.A.L.-V.; validation, J.O.-O.; experimental assays, R.A.-A., J.A.N.-H., and L.D.C.A.-R.; formal analysis, R.A.-A. and O.D.M.-H.; resources, M.A.J.-L.; writing—original draft preparation, R.A.-A.; writing—review and editing, B.I.-A. and J.O.-N.; project administration, B.I.-A.; funding acquisition, B.I.-A. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by a grant from CONACYT, Mexico (Fondo Sectorial de Investigación para la Educación SEP-CONACYT, grant number 288612).

Institutional Review Board Statement

This study was conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the Bioethical Committee of the Universidad Autónoma de Guerrero.

Informed Consent Statement

Informed consent was obtained from all participants.

Data Availability Statement

Data generated and analyzed in this study are available upon request from the authors. The sequence data are available in GenBank (https://www.ncbi.nlm.nih.gov/genbank/, accessed on 19 June 2021) with the accession numbers MW452666-MW452855.

Acknowledgments

The authors are grateful to Natividad Sales Linares for her expert technical assistance.

Conflicts of Interest

The authors declare that there are no conflict of interests.

References

  1. Zur Hausen, H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342–350. [Google Scholar] [CrossRef]
  2. De Sanjose, S.; Quint, W.G.; Alemany, L.; Geraets, D.T.; Klaustermeier, J.E.; Lloveras, B.; Tous, S.; Felix, A.; Bravo, L.E.; Shin, H.R.; et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11, 1048–1056. [Google Scholar] [CrossRef]
  3. Guan, P.; Howell-Jones, R.; Li, N.; Bruni, L.; de Sanjosé, S.; Franceschi, S.; Clifford, G.M. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int. J. Cancer 2012, 131, 2349–2359. [Google Scholar] [CrossRef] [PubMed]
  4. Ghittoni, R.; Accardi, R.; Hasan, U.; Gheit, T.; Sylla, B.; Tommasino, M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40, 1–13. [Google Scholar] [CrossRef]
  5. Boulenouar, S.; Weyn, C.; Van Noppen, M.; Moussa, A.M.; Favre, M.; Delvenne, P.O.; Bex, F.; Noël, A.; Englert, Y.; Fontaine, V. Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells. Carcinogenesis 2010, 31, 473–480. [Google Scholar] [CrossRef] [Green Version]
  6. Hu, D.; Zhou, J.; Wang, F.; Shi, H.; Li, Y.; Li, B. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo. Arch. Gynecol. Obstet. 2015, 292, 1345–1354. [Google Scholar] [CrossRef]
  7. Zheng, Y.; Zhang, J.; Rao, Z. Ribozyme targeting HPV16 E6E7 transcripts in cervical cancer cells suppresses cell growth and sensitizes cells to chemotherapy and radiotherapy. Cancer Biol. Ther. 2004, 3, 1129–1134; discussion 1135–1136. [Google Scholar] [CrossRef] [Green Version]
  8. Stacey, S.N.; Jordan, D.; Snijders, P.J.; Mackett, M.; Walboomers, J.M.; Arrand, J.R. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J. Virol. 1995, 69, 7023–7031. [Google Scholar] [CrossRef] [Green Version]
  9. Del Moral-Hernández, O.; López-Urrutia, E.; Bonilla-Moreno, R.; Martínez-Salazar, M.; Arechaga-Ocampo, E.; Berumen, J.; Villegas-Sepúlveda, N. The HPV-16 E7 oncoprotein is expressed mainly from the unspliced E6/E7 transcript in cervical carcinoma C33-A cells. Arch. Virol. 2010, 155, 1959–1970. [Google Scholar] [CrossRef] [PubMed]
  10. De Villiers, E.M.; Fauquet, C.; Broker, T.R.; Bernard, H.U.; zur Hausen, H. Classification of papillomaviruses. Virology 2004, 324, 17–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Xi, L.F.; Koutsky, L.A.; Hildesheim, A.; Galloway, D.A.; Wheeler, C.M.; Winer, R.L.; Ho, J.; Kiviat, N.B. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol. Biomark. Prev. 2007, 16, 4–10. [Google Scholar] [CrossRef] [Green Version]
  12. Burk, R.D.; Harari, A.; Chen, Z. Human papillomavirus genome variants. Virology 2013, 445, 232–243. [Google Scholar] [CrossRef] [Green Version]
  13. Mirabello, L.; Yeager, M.; Yu, K.; Clifford, G.M.; Xiao, Y.; Zhu, B.; Cullen, M.; Boland, J.F.; Wentzensen, N.; Nelson, C.W.; et al. HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell 2017, 170, 1164–1174.e1166. [Google Scholar] [CrossRef] [Green Version]
  14. Mirabello, L.; Yeager, M.; Cullen, M.; Boland, J.F.; Chen, Z.; Wentzensen, N.; Zhang, X.; Yu, K.; Yang, Q.; Mitchell, J.; et al. HPV16 Sublineage Associations with Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women. J. Natl. Cancer Inst. 2016, 108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Cornet, I.; Gheit, T.; Franceschi, S.; Vignat, J.; Burk, R.D.; Sylla, B.S.; Tommasino, M.; Clifford, G.M. Human papillomavirus type 16 genetic variants: Phylogeny and classification based on E6 and LCR. J. Virol. 2012, 86, 6855–6861. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Cornet, I.; Gheit, T.; Clifford, G.M.; Combes, J.D.; Dalstein, V.; Franceschi, S.; Tommasino, M.; Clavel, C. Human papillomavirus type 16 E6 variants in France and risk of viral persistence. Infect. Agents Cancer 2013, 8, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Berumen, J.; Ordoñez, R.M.; Lazcano, E.; Salmeron, J.; Galvan, S.C.; Estrada, R.A.; Yunes, E.; Garcia-Carranca, A.; Gonzalez-Lira, G.; Madrigal-de la Campa, A. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: A case-control study. J. Natl. Cancer Inst. 2001, 93, 1325–1330. [Google Scholar] [CrossRef] [PubMed]
  18. Pérez-Quintanilla, M.; Méndez-Martínez, R.; Vázquez-Vega, S.; Espinosa-Romero, R.; Sotelo-Regil, R.; Pérez-Montiel, M.D.; Ramos-Alamillo, U.; Cabrera-López, T.J.; Barquet-Muñoz, S.A.; Pérez-Plascencia, C.; et al. High prevalence of human papillomavirus and European variants of HPV 16 infecting concomitantly to cervix and oral cavity in HIV positive women. PLoS ONE 2020, 15, e0227900. [Google Scholar] [CrossRef] [Green Version]
  19. Escobar-Escamilla, N.; González-Martínez, B.E.; Araiza-Rodríguez, A.; Fragoso-Fonseca, D.E.; Pedroza-Torres, A.; Landa-Flores, M.G.; Garcés-Ayala, F.; Mendieta-Condado, E.; Díaz-Quiñonez, J.A.; Castro-Escarpulli, G.; et al. Mutational landscape and intra-host diversity of human papillomavirus type 16 long control region and E6 variants in cervical samples. Arch. Virol. 2019, 164, 2953–2961. [Google Scholar] [CrossRef] [PubMed]
  20. González-Losa, M.d.R.; Rosado-Lopez, I.; Valdez-González, N.; Puerto-Solís, M. High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. J. Clin. Virol. 2004, 29, 202–205. [Google Scholar] [CrossRef]
  21. Ortiz-Ortiz, J.; Alarcón-Romero, L.d.C.; Jiménez-López, M.A.; Garzón-Barrientos, V.H.; Calleja-Macías, I.; Barrera-Saldaña, H.A.; Leyva-Vázquez, M.A.; Illades-Aguiar, B. Association of human papillomavirus 16 E6 variants with cervical carcinoma and precursor lesions in women from Southern Mexico. Virol. J. 2015, 12, 29. [Google Scholar] [CrossRef] [Green Version]
  22. Zacapala-Gómez, A.E.; Del Moral-Hernández, O.; Villegas-Sepúlveda, N.; Hidalgo-Miranda, A.; Romero-Córdoba, S.L.; Beltrán-Anaya, F.O.; Leyva-Vázquez, M.A.; Alarcón-Romero, L.d.C.; Illades-Aguiar, B. Changes in global gene expression profiles induced by HPV 16 E6 oncoprotein variants in cervical carcinoma C33-A cells. Virology 2016, 488, 187–195. [Google Scholar] [CrossRef] [Green Version]
  23. Wu, Y.; Chen, Y.; Li, L.; Yu, G.; He, Y.; Zhang, Y. Analysis of mutations in the E6/E7 oncogenes and L1 gene of human papillomavirus 16 cervical cancer isolates from China. J. Gen. Virol. 2006, 87, 1181–1188. [Google Scholar] [CrossRef]
  24. Lee, C.W.; Bae, J.H.; Lee, S.J.; Ho, E.M.; Lee, I.H.; Park, Y.G.; Park, J.S. Distribution of human papillomavirus type 16 E6 and E7 gene variants in the progression of cervical dysplasia in Korean women. J. Obstet. Gynaecol. Res. 2011, 37, 1320–1326. [Google Scholar] [CrossRef] [PubMed]
  25. Zine El Abidine, A.; Tomaić, V.; Bel Haj Rhouma, R.; Massimi, P.; Guizani, I.; Boubaker, S.; Ennaifer, E.; Banks, L. A naturally occurring variant of HPV-16 E7 exerts increased transforming activity through acquisition of an additional phospho-acceptor site. Virology 2017, 500, 218–225. [Google Scholar] [CrossRef] [PubMed]
  26. Icenogle, J.P.; Sathya, P.; Miller, D.L.; Tucker, R.A.; Rawls, W.E. Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16. Virology 1991, 184, 101–107. [Google Scholar] [CrossRef]
  27. De Boer, M.A.; Peters, L.A.; Aziz, M.F.; Siregar, B.; Cornain, S.; Vrede, M.A.; Jordanova, E.S.; Kolkman-Uljee, S.; Fleuren, G.J. Human papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and The Netherlands. Gynecol. Oncol. 2004, 94, 488–494. [Google Scholar] [CrossRef]
  28. Swan, D.C.; Rajeevan, M.; Tortolero-Luna, G.; Follen, M.; Tucker, R.A.; Unger, E.R. Human papillomavirus type 16 E2 and E6/E7 variants. Gynecol. Oncol. 2005, 96, 695–700. [Google Scholar] [CrossRef] [PubMed]
  29. Chansaenroj, J.; Theamboonlers, A.; Junyangdikul, P.; Swangvaree, S.; Karalak, A.; Poovorawan, Y. Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac. J. Cancer Prev. 2012, 13, 599–606. [Google Scholar] [CrossRef] [Green Version]
  30. Mazumder Indra, D.; Singh, R.K.; Mitra, S.; Dutta, S.; Chakraborty, C.; Basu, P.S.; Mondal, R.K.; Roychoudhury, S.; Panda, C.K. Genetic and epigenetic changes of HPV16 in cervical cancer differentially regulate E6/E7 expression and associate with disease progression. Gynecol. Oncol. 2011, 123, 597–604. [Google Scholar] [CrossRef]
  31. Chang, Y.J.; Chen, H.C.; Pan, M.H.; Lee, B.H.; You, S.L.; Lin, C.Y.; Chou, Y.C.; Hsieh, C.Y.; Cheng, Y.J.; Liaw, K.L.; et al. Intratypic variants of human papillomavirus type 16 and risk of cervical neoplasia in Taiwan. J. Med. Virol. 2013, 85, 1567–1576. [Google Scholar] [CrossRef]
  32. Bali, V.; Bebok, Z. Decoding mechanisms by which silent codon changes influence protein biogenesis and function. Int. J. Biochem. Cell Biol. 2015, 64, 58–74. [Google Scholar] [CrossRef] [Green Version]
  33. Hunt, R.; Sauna, Z.E.; Ambudkar, S.V.; Gottesman, M.M.; Kimchi-Sarfaty, C. Silent (synonymous) SNPs: Should we care about them? Methods Mol. Biol. 2009, 578, 23–39. [Google Scholar] [CrossRef] [PubMed]
  34. Eschle, D.; Dürst, M.; ter Meulen, J.; Luande, J.; Eberhardt, H.C.; Pawlita, M.; Gissmann, L. Geographical dependence of sequence variation in the E7 gene of human papillomavirus type 16. J. Gen. Virol. 1992, 73 Pt 7, 1829–1832. [Google Scholar] [CrossRef]
  35. Buonaguro, F.M.; Tornesello, M.L.; Salatiello, I.; Okong, P.; Buonaguro, L.; Beth-Giraldo, E.; Biryahwaho, B.; Sempala, S.D.; Giraldo, G. The uganda study on HPV variants and genital cancers. J. Clin. Virol. 2000, 19, 31–41. [Google Scholar] [CrossRef]
  36. Boumba, L.M.; Assoumou, S.Z.; Hilali, L.; Mambou, J.V.; Moukassa, D.; Ennaji, M.M. Genetic variability in E6 and E7 oncogenes of human papillomavirus Type 16 from Congolese cervical cancer isolates. Infect. Agents Cancer 2015, 10, 15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Ramas, V.; Mirazo, S.; Bonilla, S.; Ruchansky, D.; Arbiza, J. Analysis of human papillomavirus 16 E6, E7 genes and Long Control Region in cervical samples from Uruguayan women. Gene 2018, 654, 103–109. [Google Scholar] [CrossRef] [PubMed]
  38. Smits, H.L.; Traanberg, K.F.; Krul, M.R.; Prussia, P.R.; Kuiken, C.L.; Jebbink, M.F.; Kleyne, J.A.; van den Berg, R.H.; Capone, B.; de Bruyn, A.; et al. Identification of a unique group of human papillomavirus type 16 sequence variants among clinical isolates from Barbados. J. Gen. Virol. 1994, 75 Pt 9, 2457–2462. [Google Scholar] [CrossRef] [PubMed]
  39. Safaeian, M.; van Doorslaer, K.; Schiffman, M.; Chen, Z.; Rodriguez, A.C.; Herrero, R.; Hildesheim, A.; Burk, R.D. Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties. Arch. Virol. 2010, 155, 367–370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Zhang, L.; Liao, H.; Yang, B.; Geffre, C.P.; Zhang, A.; Zhou, A.; Cao, H.; Wang, J.; Zhang, Z.; Zheng, W. Variants of human papillomavirus type 16 predispose toward persistent infection. Int. J. Clin. Exp. Pathol. 2015, 8, 8453–8459. [Google Scholar] [PubMed]
  41. Ding, T.; Wang, X.; Ye, F.; Cheng, X.; Lu, W.; Xie, X. Distribution of human papillomavirus 16 E6/E7 variants in cervical cancer and intraepithelial neoplasia in Chinese women. Int. J. Gynecol. Cancer 2010, 20, 1391–1398. [Google Scholar] [CrossRef] [PubMed]
  42. Zhao, J.; Zhu, J.; Guo, J.; Zhu, T.; Zhong, J.; Liu, M.; Ruan, Y.; Liao, S.; Li, F. Genetic variability and functional implication of HPV16 from cervical intraepithelial neoplasia in Shanghai women. J. Med. Virol. 2020, 92, 372–381. [Google Scholar] [CrossRef] [PubMed]
  43. Cao, M.; Chenzhang, Y.; Ding, X.; Zhang, Y.; Jing, Y.; Chen, Z. Genetic variability and lineage phylogeny of human papillomavirus type-16 and -53 based on the E6, E7, and L1 genes in Southwest China. Gene 2016, 592, 49–59. [Google Scholar] [CrossRef] [PubMed]
  44. Sun, M.; Gao, L.; Liu, Y.; Zhao, Y.; Wang, X.; Pan, Y.; Ning, T.; Cai, H.; Yang, H.; Zhai, W.; et al. Whole genome sequencing and evolutionary analysis of human papillomavirus type 16 in central China. PLoS ONE 2012, 7, e36577. [Google Scholar] [CrossRef] [Green Version]
  45. Yang, L.; Yang, H.; Wu, K.; Shi, X.; Ma, S.; Sun, Q. Prevalence of HPV and variation of HPV 16/HPV 18 E6/E7 genes in cervical cancer in women in South West China. J. Med. Virol. 2014, 86, 1926–1936. [Google Scholar] [CrossRef]
  46. Fujinaga, Y.; Okazawa, K.; Nishikawa, A.; Yamakawa, Y.; Fukushima, M.; Kato, I.; Fujinaga, K. Sequence variation of human papillomavirus type 16 E7 in preinvasive and invasive cervical neoplasias. Virus Genes 1994, 9, 85–92. [Google Scholar] [CrossRef]
  47. Ishizaki, A.; Matsushita, K.; Hoang, H.T.; Agdamag, D.M.; Nguyen, C.H.; Tran, V.T.; Sasagawa, T.; Saikawa, K.; Lihana, R.; Pham, H.V.; et al. E6 and E7 variants of human papillomavirus-16 and -52 in Japan, the Philippines, and Vietnam. J. Med. Virol. 2013, 85, 1069–1076. [Google Scholar] [CrossRef] [Green Version]
  48. Park, J.S.; Shin, S.; Kim, E.C.; Kim, J.E.; Kim, Y.B.; Oh, S.; Roh, E.Y.; Yoon, J.H. Association of human papillomavirus type 16 and its genetic variants with cervical lesion in Korea. APMIS 2016, 124, 950–957. [Google Scholar] [CrossRef]
  49. Choi, B.S.; Kim, S.S.; Yun, H.; Jang, D.H.; Lee, J.S. Distinctive distribution of HPV16 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers. J. Med. Virol. 2007, 79, 426–430. [Google Scholar] [CrossRef]
  50. Song, Y.S.; Kee, S.H.; Kim, J.W.; Park, N.H.; Kang, S.B.; Chang, W.H.; Lee, H.P. Major sequence variants in E7 gene of human papillomavirus type 16 from cervical cancerous and noncancerous lesions of Korean women. Gynecol. Oncol. 1997, 66, 275–281. [Google Scholar] [CrossRef]
  51. Radhakrishna Pillai, M.; Sreevidya, S.; Pollock, B.H.; Jayaprakash, P.G.; Herman, B. Human papillomavirus type 16 E6 and E7 gene variations in Indian cervical cancer. Gynecol Oncol. 2002, 87, 268–273. [Google Scholar] [CrossRef]
  52. He, H.; Li, H.; Fan, P.; Zhu, J.; Pan, Z.; Pan, H.; Wu, D.; Ren, X.; Guo, X.; Li, D.; et al. Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China. Infect. Agent Cancer 2016, 11, 44. [Google Scholar] [CrossRef]
  53. Zhao, J.; Zhan, Q.; Guo, J.; Liu, M.; Ruan, Y.; Zhu, T.; Han, L.; Li, F. Phylogeny and polymorphism in the E6 and E7 of human papillomavirus: alpha-9 (HPV16, 31, 33, 52, 58), alpha-5 (HPV51), alpha-6 (HPV53, 66), alpha-7 (HPV18, 39, 59, 68) and alpha-10 (HPV6, 44) in women from Shanghai. Infect. Agents Cancer 2019, 14, 38. [Google Scholar] [CrossRef] [PubMed]
  54. Vaeteewoottacharn, K.; Jearanaikoon, P.; Ponglikitmongkol, M. Co-mutation of HPV16 E6 and E7 genes in Thai squamous cervical carcinomas. Anticancer Res. 2003, 23, 1927–1931. [Google Scholar]
  55. Zhang, L.; Yang, B.; Zhang, A.; Zhou, A.; Yuan, J.; Wang, Y.; Sun, L.; Cao, H.; Wang, J.; Zheng, W. Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization. J. Med. Virol. 2016, 88, 1982–1988. [Google Scholar] [CrossRef] [PubMed]
  56. Shang, Q.; Wang, Y.; Fang, Y.; Wei, L.; Chen, S.; Sun, Y.; Li, B.; Zhang, F.; Gu, H. Human papillomavirus type 16 variant analysis of E6, E7, and L1 [corrected] genes and long control region in [corrected] cervical carcinomas in patients in northeast China. J. Clin. Microbiol. 2011, 49, 2656–2663. [Google Scholar] [CrossRef] [Green Version]
  57. Pande, S.; Jain, N.; Prusty, B.K.; Bhambhani, S.; Gupta, S.; Sharma, R.; Batra, S.; Das, B.C. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J. Clin. Microbiol. 2008, 46, 1060–1066. [Google Scholar] [CrossRef] [Green Version]
  58. Plesa, A.; Anton, G.; Iancu, I.V.; Diaconu, C.C.; Huica, I.; Stanescu, A.D.; Socolov, D.; Nistor, E.; Popa, E.; Stoian, M.; et al. Molecular variants of human papilloma virus 16 E2, E4, E5, E6 and E7 genes associated with cervical neoplasia in Romanian patients. Arch. Virol. 2014, 159, 3305–3320. [Google Scholar] [CrossRef] [PubMed]
  59. Nindl, I.; Rindfleisch, K.; Lotz, B.; Schneider, A.; Dürst, M. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int. J. Cancer 1999, 82, 203–207. [Google Scholar] [CrossRef]
  60. Hu, X.; Pang, T.; Guo, Z.; Pontén, J.; Nistér, M.; Bernard Afink, G. Oncogene lineages of human papillomavirus type 16 E6, E7 and E5 in preinvasive and invasive cervical squamous cell carcinoma. J. Pathol. 2001, 195, 307–311. [Google Scholar] [CrossRef]
  61. Vrtačnik Bokal, E.; Kocjan, B.J.; Poljak, M.; Bogovac, Z.; Jančar, N. Genomic variants of human papillomavirus genotypes 16, 18, and 33 in women with cervical cancer in Slovenia. J. Obstet. Gynaecol. Res. 2010, 36, 1204–1213. [Google Scholar] [CrossRef]
  62. Tornesello, M.L.; Duraturo, M.L.; Salatiello, I.; Buonaguro, L.; Losito, S.; Botti, G.; Stellato, G.; Greggi, S.; Piccoli, R.; Pilotti, S.; et al. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J. Med. Virol. 2004, 74, 117–126. [Google Scholar] [CrossRef]
  63. Garbuglia, A.R.; Carletti, F.; Minosse, C.; Piselli, P.; Zaniratti, M.S.; Serraino, D.; Capobianchi, M.R. Genetic variability in E6 and E7 genes of human papillomavirus -16, -18, -31 and -33 from HIV-1-positive women in Italy. New Microbiol. 2007, 30, 377–382. [Google Scholar]
  64. Cento, V.; Ciccozzi, M.; Ronga, L.; Perno, C.F.; Ciotti, M. Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions. J. Med. Virol. 2009, 81, 1627–1634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Benedet, J.L.; Bender, H.; Jones, H., 3rd; Ngan, H.Y.; Pecorelli, S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J. Gynaecol. Obstet. 2000, 70, 209–262. [Google Scholar] [CrossRef]
  66. Solomon, D.; Davey, D.; Kurman, R.; Moriarty, A.; O’Connor, D.; Prey, M.; Raab, S.; Sherman, M.; Wilbur, D.; Wright, T., Jr.; et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 2002, 287, 2114–2119. [Google Scholar] [CrossRef] [PubMed]
  67. Illades-Aguiar, B.; Del Carmen Alarcón-Romero, L.; Antonio-Véjar, V.; Zamudio-López, N.; Sales-Linares, N.; Flores-Alfaro, E.; Fernández-Tilapa, G.; Vences-Velázquez, A.; Muñoz-Valle, J.F.; Leyva-Vázquez, M.-A. Prevalence and Distribution of Human Papillomavirus Types in Cervical Cancer, Squamous Intraepithelial Lesions, and with No Intraepithelial Lesions in Women from Southern Mexico. Gynecol. Oncol. 2010, 117, 291–296. [Google Scholar] [CrossRef]
  68. Davis, L. Basic Methods in Molecular Biology; Elsevier: Amsterdam, The Netherlands, 2012; ISBN 978-0-444-60149-0. [Google Scholar]
  69. Vossler, J.L.; Forbes, B.A.; Adelson, M.D. Evaluation of the Polymerase Chain Reaction for the Detection of Human Papillomavirus from Urine. J. Med. Virol. 1995, 45, 354–360. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Clinical and demographic characteristics of patients included in the study.
Table 1. Clinical and demographic characteristics of patients included in the study.
Non ILLSILHSILCCTotalp
n%n%n%n%n%
Mean age35.9 30.2 36.3 50.5 38.6 <0.005
Age<0.005
<312545.454058.82350.0034.927137.37
31–401221.821927.94116.671321.314523.68
41–51916.36710.29233.331931.153719.47
>51916.3622.94002642.623719.47
Age at menarche0.363
<143258.184363.233503150.8210957.37
14–162341.822130.883502337.707036.84
>160034.410046.5673.68
Did not answer0011.470034.9242.11
Age at menopause<0.005
<4535.4511.47116.671118.03168.42
45–49712.7322.94001321.312211.58
>4947.2700116.6746.5694.74
No menopause3970.916392.65466.672032.7912666.32
Did not answer23.6422.94001321.31178.95
Age at first sexual intercourse<0.005
<1659.0968.82001829.512915.26
16–203665.453754.41583.333252.4611057.89
>201424.452435.29116.67813.114724.74
Did not answer0011.470034.9242.11
Geographical region of Guerrero<0.005
Costa Chica0011.4700711.4884.21
Costa Grande000000914.7594.74
La Montaña35.4568.820058.20147.37
Tierra Caliente11.82000023.2831.58
Acapulco59.0968.82001118.032211.58
Zona Centro4174.555175.0061001016.3910856.84
Zona Norte23.6434.4100914.75147.37
Did not answer35.4511.4700813.11126.32
Total5510068100610061100190100
Abbreviations: Non IL, non intraepithelial lesions; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions; CC, cervical carcinoma.
Table
Table 2. Frequency of HPV 16 E7 genetic variants and their association with cervical carcinoma and precursor lesions in women from southern Mexico.
Table 2. Frequency of HPV 16 E7 genetic variants and their association with cervical carcinoma and precursor lesions in women from southern Mexico.
E7 Region Frequency
647666678712732765789795Non ILLSILHSILCCTotal
VariantsAGTCTCTTAa Change in E7 an%n%OR
(95% CI)		pn%OR
(95% CI)		pn%OR
(95% CI)		pn%
E7-prototype---------4887.275377.941 b-350.01 b-3862.291 b-14274.74
E7-C732/C789/G795----c-cg-712.72811.761.03
(0.35–3.07)		0.950350.06.86
(1.15–40.9)		0.352134.423.79
(1.46–9.85)		0.0063920.53
E7-A666-a-------00.0022.94--00.00--23.28--42.11
E7-A712---A----H51N00.0022.94--00.00--00.00--21.05
E7-C678--c------00.0011.47--00.00--00.00--10.53
E7-T765-----t---00.0011.47--00.00--00.00--10.53
E7-G647/C789/G795G-----cgN29S00.0011.47--00.00--00.00--10.53
Total14123914040 5510068100 6100 61100 190100
Note: Capital letters indicate the mutations that generate amino acid change and lowercase letters indicate mutation without amino acid change. Abbreviations: Non IL, non intraepithelial lesions; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions; CC, cervical carcinoma; CI, confidence interval; OR, odd ratio. a, the amino acid change prediction was made on HPV 16 reference, sequence NC 1526.3. b, indicates reference category (E7-Prototype).
Table
Table 3. Frequency of combinations of E6 and E7 variants in the HPV 16 E6/E7 bicistron and its associations with cervical carcinoma and precursor lesions.
Table 3. Frequency of combinations of E6 and E7 variants in the HPV 16 E6/E7 bicistron and its associations with cervical carcinoma and precursor lesions.
Non ILLSILHSILCCTotal
SublineageE6 VariantsE7 Variantsn%n%OR (95% IC)pn%OR (95% IC)pn%OR (95% IC)pn%
A1 1323.6710.3 116.7 34.9 2412.6
E-prototypeE7-prototype1018.2710.31 a-00--11.61 a-189.5
E-prototypeE7-732/C789/G79511.800--116.7--00--21.1
E-G131E7-prototype11.800--00--23.320 (0.85–471.57)0.06331.6
E-G131E7-732/C789/G79511.800--00--00--10.5
A2 3869.15175 233.3 3659 12766.8
E-G350E7-prototype2341.82942.61.8 (0.59–5.47)0.29233.3--1626.26.95 (0.8–59.9)0.087036.8
E-G350E7-A6660022.9--00--23.3--42.1
E-G350E7-A7120011.5--00--00--10.5
E-G350E7-T7650011.5--00--00--10.5
E-G350E7-732/C789/G79523.600--00--11.65 (0.21–117.89)0.3231.6
E-C109/G350E7-prototype0011.5--00--23.3--31.6
E-G110/G350E7-prototype11.811.5--00--00--21.1
E-G131/G350E7-prototype0000--00--11.6--10.5
E-131/C188/G350E7-prototype11.811.5--00--00--21.1
E-A176/G350E7-prototype35.522.90.95 (0.12–7.28)0.9600--711.523.33 (1.99–273.3)0.012126.3
E-A176/G350E7-732/C789/G7950000--00--11.6--10.5
E-C182/G350E7-prototype11.811.5--00--00--21.1
E-T182/G350E7-prototype0000--00--11.6--10.5
E-C183/G350E7-prototype35.511.5--00--00--42.1
E-G185/G350E7-prototype0000--00--11.6--10.5
E-A188/G350E7-prototype0000--00--11.6--10.5
E-C188/G350E7-prototype23.657.4--00--34.9--105.3
E-C188/G350E7-C6780011.5--00--00--10.5
E-C188/G350E7-A7120011.5--00--00--10.5
E-C188/G310/G350E7-prototype11.811.5--00--00--21.1
E-G189/T256/G350E7-prototype0011.5--00--00--10.5
E-G257/G350E7-prototype0011.5--00--00--10.5
E-C442/G350E7-prototype11.800--00--00--10.5
E-G535/G350E7-prototype0011.5--00--00--10.5
C1 0011.5 00 00 10.5
Af2-a/C109/G403E7-647/C789/G7950011.5--00--00--10.5
D2 47.3913.2 350 2236.1 3820.0
AA-aE7-prototype11.811.5--00--00--21.1
AA-aE7-732/C789/G79511.857.47.14 (0.68–75.22)0.10233.3--1118110 (6.04–2001.3)0.0011910.0
AA-cE7-prototype0000--116.7--34.9--42.1
AA-cE7-732/C789/G79523.634.42.14 (0.28–16.37)0.4600--711.535 (2.63–465.37)0.007126.3
AA-c/G185E7-732/C789/G7950000--00--11.6--10.5
Total 5510068100 6100 61100 190100
Abbreviations: Non IL, non intraepithelial lesions; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions; CC, cervical carcinoma; CI, confidence interval; OR, odd ratio. a Indicates reference category (E-prototype*E7-Prototype).
Table
Table 4. Most frequent HPV 16 E7 variants reported around the world.
Table 4. Most frequent HPV 16 E7 variants reported around the world.
E7 HPV16 VariantE7-prototype
VariantTotalCCNon-IL/SILTotalCCTotalCCCountryReference
NNNN%N%N%N%
Africa
E7-C789/G79521210943943314314TanzaniaEschle et al., 1992 [34]
E7-C789/G795532510031000000UgandaBuonaguro et al., 2000 [35]
E7-C789/G7951313013100131000000CongoBoumba et al., 2015 [36]
America
E7-C732/C789/G7951906112939212134142753862MexicoThis study
E7-C732/C789/G7951000100161600727200EU(Texas)Swan et al., 2005 [28]
E7-C732/C789/G7952525031231215601560SurinameDe Boer et al., 2004 [27]
E7-C732/C789/G79515NDND320NDND853NDNDPanama, EUIcenogle et al., 1991 [26]
E7-A712120122170065000UruguayRamas et al., 2018 [37]
E7-C789/G79511110655655327327BarbadosSmits et al., 1994 [38]
E7-C73252NDND713NDNDNDNDNDNDCosta RicaSafaenian et al., 2010 [39]
E7-C78952NDND815NDNDNDNDNDNDCosta RicaSafaenian et al., 2010 [39]
E7-G79552NDND815NDNDNDNDNDNDCosta RicaSafaenian et al., 2010 [39]
Asia
E7-G647/C846292029212543001254300ChinaZhang et al., 2015 [40]
E7-G647/C846167531141267537707424ChinaDing et al., 2010 [41]
E7-G647/C84698098636400141400ChinaZhao et al., 2020 [42]
E7-G647/C84697097626400131300ChinaCao et al., 2016 [43]
E7-G647/C846767602634263415201520ChinaSun et al., 2012 [44]
E7-G647/C84647470296229620000ChinaWu et al., 2006 [23]
E7-G647/C84658382036622668NDND13ChinaYang et al., 2014 [45]
E7-G647/C8461574311412882419543NDNDTaiwanChang et al., 2013 [31]
E7-G647/C8461596640556320222JapanFujinaga et al., 1994 [46]
E7-G647/C8463103118580021000JapanIshizaki et al., 2013 [47]
E7-G647/C8462402452100187500PhilippinesIshizaki et al., 2013 [47]
E7-G647/C846240242083000000VietnamIshizaki et al., 2013 [47]
E7-G647/C846990333333333333ThailandChansaenroj et al., 2012 [29]
E7-C732/C789/G795990333333333333ThailandChansaenroj et al., 2012 [29]
E7-G64714125116634518725539520KoreaLee et al., 2011 [24]
E7-G64713331102118895541151127KoreaPark et al., 2016 [48]
E7-G6475605636640071300KoreaChoi et al., 2007 [49]
E7-G64742271525601970819311KoreaSong et al., 1997 [50]
E7-G647143816254382936NDNDNDNDIndiaRadhakrishna Pillai et al., 2002 [51]
E7-G64743430121242984298ChinaHe et al., 2016 [52]
E7-G64731031247700NDND00ChinaZhao et al., 2019 [53]
E7-G6473131019611961929929ThailandVaeteewoottacharn et al., 2003 [54]
E7-C6461000100212100NDND00ChinaZhang et al., 2016 [55]
E7-A6665252020392039815815ChinaShang et al., 2011 [56]
E7-A66622220156815682929IndonesiaDe Boer et al., 2004 [27]
E7-C789/G79560600353552875287India (North)Pande et al., 2008 [57]
E7-C732/C789/G79511094161211111295868085IndiaMazumder Indra et al., 2011 [30]
Europe
E7-C732/T749/G795124289687414103831968Romania Plesa et al., 2014 [58]
E7-G8221123775151341189803287GermanyNindl et al., 1999 [59]
E7-G822613130472755902787SwedenHu et al., 2001 [60]
E7-G82240400252535883588SloveniaVrtačnik Bokal et al., 2010 [61]
E7-C789/G795903654101141171792467ItalyTornesello et al., 2004 [62]
E7-C789/G795140141700139300ItalyGarbuglia et al., 2007 [63]
E7-C789/G7952727031131121782178NetherlandsDe Boer et al., 2004 [27]
E7-C732/C789/G795290291300279300ItalyCento et al., 2009 [64]
E7-T616835113133788267NetherlandsSmits et al., 1994 [38]
-660000061006100GermanyEschle et al., 1992 [34]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Antaño-Arias, R.; Del Moral-Hernández, O.; Ortiz-Ortiz, J.; Alarcón-Romero, L.D.C.; Navor-Hernández, J.A.; Leyva-Vázquez, M.A.; Jiménez-López, M.A.; Organista-Nava, J.; Illades-Aguiar, B. E6/E7 Variants of Human Papillomavirus 16 Associated with Cervical Carcinoma in Women in Southern Mexico. Pathogens 2021, 10, 773. https://doi.org/10.3390/pathogens10060773

AMA Style

Antaño-Arias R, Del Moral-Hernández O, Ortiz-Ortiz J, Alarcón-Romero LDC, Navor-Hernández JA, Leyva-Vázquez MA, Jiménez-López MA, Organista-Nava J, Illades-Aguiar B. E6/E7 Variants of Human Papillomavirus 16 Associated with Cervical Carcinoma in Women in Southern Mexico. Pathogens. 2021; 10(6):773. https://doi.org/10.3390/pathogens10060773

Chicago/Turabian Style

Antaño-Arias, Ramón, Oscar Del Moral-Hernández, Julio Ortiz-Ortiz, Luz Del Carmen Alarcón-Romero, Jorge Adán Navor-Hernández, Marco Antonio Leyva-Vázquez, Marco Antonio Jiménez-López, Jorge Organista-Nava, and Berenice Illades-Aguiar. 2021. "E6/E7 Variants of Human Papillomavirus 16 Associated with Cervical Carcinoma in Women in Southern Mexico" Pathogens 10, no. 6: 773. https://doi.org/10.3390/pathogens10060773

APA Style

Antaño-Arias, R., Del Moral-Hernández, O., Ortiz-Ortiz, J., Alarcón-Romero, L. D. C., Navor-Hernández, J. A., Leyva-Vázquez, M. A., Jiménez-López, M. A., Organista-Nava, J., & Illades-Aguiar, B. (2021). E6/E7 Variants of Human Papillomavirus 16 Associated with Cervical Carcinoma in Women in Southern Mexico. Pathogens, 10(6), 773. https://doi.org/10.3390/pathogens10060773

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop